Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07BVI
|
|||
| Former ID |
DAP001561
|
|||
| Drug Name |
Ipilimumab
|
|||
| Synonyms |
BMS-734016; MDX-010; MDX-101; Yervoy (TN)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30] | Approved | [1], [2], [3] | |
| Company |
Bristol-Myers Squibb
|
|||
| ADReCS Drug ID | BADD_D01190 | |||
| SuperDrug ATC ID |
L01XC11
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | Ipilimumab can be metabolized by Bacteroides fragilis, which results in the increase of the drug's activity. | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase activity | |||
| Description | Ipilimumab can be metabolized by Bacteroides thetaiotaomicron, which results in the increase of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Effect | Increase side effect (colitis) | |||
| Description | Ipilimumab can be metabolized by Bacteroidetes, which results in the increase of the drug's side effect (colitis). | |||
| Studied Microbe: Gut microbiota unspecific | [6] | |||
| Metabolic Effect | Decrease toxicity | |||
| Description | Ipilimumab can be metabolized by gut microbiota, which results in the decrease of the drug's toxicity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6888). | |||
| REF 2 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||
| REF 3 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
| REF 4 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079-84. | |||
| REF 5 | Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016 Feb 2;7:10391. | |||
| REF 6 | Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1043-1055. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.